Literature DB >> 7174795

Protective human hybridoma antibody to tetanus toxin.

F Gigliotti, R A Insel.   

Abstract

Postimmunization human B lymphocytes and mouse myeloma cells were fused to produce interspecies hybridomas secreting human antibody of predefined specificity with an initial frequency comparable to intraspecies fusion. After 13 mo in culture, one clone continued to secrete high titers of human IgG antitetanus toxin antibody. This antibody binds to the B fragment of tetanus toxin and protects mice against tetanus. The demonstration of in vivo protection with a human monoclonal antibody is an important first step towards the ultimate goal of human administration of monoclonal antibodies for the prevention and therapy of human infections.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7174795      PMCID： PMC370348          DOI： 10.1172/jci110730

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  21 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

Review 2.  Tetanus toxin.

Authors:  B Bizzini
Journal:  Microbiol Rev       Date:  1979-06

3.  Isolation and purification of two antigenically active, "complimentary" polypeptide fragments of tetanus neurotoxin.

Authors:  M Matsuda; M Yoneda
Journal:  Infect Immun       Date:  1975-11       Impact factor: 3.441

4.  Characterization of a circulating subpopulation of spontaneous antitetanus toxoid antibody producing B cells following in vivo booster immunization.

Authors:  R H Stevens; E Macy; C Morrow; A Saxon
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

5.  Structure of tetanus toxin. II. Toxin binding to ganglioside.

Authors:  T B Helting; O Zwisler; H Wiegandt
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

6.  Structure of tetanus toxin. I. Breakdown of the toxin molecule and discrimination between polypeptide fragments.

Authors:  T B Helting; O Zwisler
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

7.  Single step separation of human T and B cells using AET treated srbc rosettes.

Authors:  A Saxon; J Feldhaus; R A Robins
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

8.  An enzymic method for the trace iodination of immunoglobulins and other proteins.

Authors:  J J Marchalonis
Journal:  Biochem J       Date:  1969-06       Impact factor: 3.857

9.  Immunization against neonatal tetanus in New Guinea. 3. The toxin-neutralization test and the response of guinea-pigs to the toxoids as used in the immunization schedules in New Guinea.

Authors:  M F Barile; M C Hardegree; M Pittman
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

10.  Human monoclonal antibody against Forssman antigen.

Authors:  R Nowinski; C Berglund; J Lane; M Lostrom; I Bernstein; W Young; S I Hakomori; L Hill; M Cooney
Journal:  Science       Date:  1980-10-31       Impact factor: 47.728
View more
  17 in total

1.  Inducible expression in plants by virus-mediated transgene activation.

Authors:  Anna K Hull; Vidadi Yusibov; Vadim Mett
Journal:  Transgenic Res       Date:  2005-08       Impact factor: 2.788

2.  Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies.

Authors:  Mehdi Yousefi; Roya Khosravi-Eghbal; Ahmad Reza Mahmoudi; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Fazel Shokri
Journal:  Hum Vaccin Immunother       Date:  2013-10-14       Impact factor: 3.452

3.  Characteristics of toxin-neutralization by anti-tetanus human monoclonal antibodies directed against the three functional domains [A], [B] and [C] of the tetanus toxin molecule and a reliable method for evaluating the protective effects of monoclonal antibodies.

Authors:  M Matsuda; M Kamei; N Sugimoto; Y Ma; S Hashizume
Journal:  Eur J Epidemiol       Date:  1992-01       Impact factor: 8.082

4.  Mammalian expression of single chain variable region fragments dimerized by Fc regions.

Authors:  T Kato; K Sato; S Suzuki; H Sasakawa; M Kurokawa; K Nishioka; K Yamamoto
Journal:  Mol Biol Rep       Date:  1995       Impact factor: 2.316

5.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1985       Impact factor: 3.553

6.  Antibodies against the light chain of tetanus toxin in human sera.

Authors:  C S Lin; W H Habig; M C Hardegree
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

Review 7.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

8.  Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin.

Authors:  Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

Review 9.  Human monoclonal antibodies.

Authors:  S P Cole; B G Campling; T Atlaw; D Kozbor; J C Roder
Journal:  Mol Cell Biochem       Date:  1984-06       Impact factor: 3.396

10.  Monoclonal antibodies as probes of tetanus toxin structure and function.

Authors:  J G Kenimer; W H Habig; M C Hardegree
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.